Nivolumab, a new life-extending drug to treat some forms of lung cancer is to be made routinely available in Wales.
This was published under the 2016 to 2021 administration of the Welsh Government
A patient access scheme between NHS Wales and the manufacturer, Bristol-Myers Squibb, means that it will be available to treat some people with advanced non-small cell lung cancer, if they have already been treated with chemotherapy.
Nivolumab, also known as Opdivo®, will be available where clinically appropriate no later than 60 days after the agreement was signed.
Health Secretary, Vaughan Gething said:
“I’m pleased NHS Wales has been able to reach an agreement with the manufacturer, which will make the drug routinely available in Wales, to patients who will benefit.
“Our £80m New Treatment Fund launched in January this year supports faster and more consistent access to medicines recommended by NICE and the AWMSG. This includes new cancer treatments – such as Nivolumab – even where the NICE recommendation is subject to a detailed agreement with the manufacturer.”